Abstract
In this issue of Blood, Rothe et al introduce a new principle of targeted Hodgkin lymphoma (HL) immunotherapy in their report from a phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Blood |
| Vol/bind | 125 |
| Udgave nummer | 26 |
| Sider (fra-til) | 3967-8 |
| Antal sider | 2 |
| ISSN | 0006-4971 |
| DOI | |
| Status | Udgivet - 25 jun. 2015 |